DIAGNOS to Present at the Centurion One Capital 3rd Annual Bahamas Summit
DIAGNOS (OTCQB: DGNOF) will present at the Centurion One Capital 3rd Annual Bahamas Summit on October 28–29, 2025 at the Rosewood Baha Mar Hotel in Nassau. CEO André Larente will present, attend investor meetings and participate on a panel.
The company noted a successful MDSAP audit and referenced pending regulatory approvals from Saudi FDA, Health Canada and the FDA. The summit runs 9:00 AM–5:00 PM EDT and features presentations, 1x1 investor meetings and panel discussions.
DIAGNOS (OTCQB: DGNOF) parteciperà alla Centurion One Capital 3ª Annual Bahamas Summit il 28–29 ottobre 2025 presso il Rosewood Baha Mar Hotel a Nassau. Il CEO André Larente terrà una presentazione, parteciperà a incontri con gli investitori e parteciperà a un panel.
L'azienda ha segnalato un audit MDSAP riuscito e ha fatto riferimento ad approvazioni normative in sospeso da Saudi FDA, Health Canada e dalla FDA. Il summit si svolge dalle 9:00 alle 17:00 EDT e prevede presentazioni, incontri investitore 1x1 e sessioni di panel.
DIAGNOS (OTCQB: DGNOF) participará en la Centurion One Capital 3rd Annual Bahamas Summit del 28 al 29 de octubre de 2025 en el Rosewood Baha Mar Hotel en Nassau. El CEO André Larente hará una presentación, asistirá a reuniones con inversionistas y participará en un panel.
La empresa señaló una auditoría MDSAP exitosa y mencionó aprobaciones regulatorias pendientes de Saudi FDA, Health Canada y la FDA. El cumbre se realiza de 9:00 AM a 5:00 PM EDT y cuenta con presentaciones, reuniones con inversionistas 1x1 y sesiones de panel.
DIAGNOS (OTCQB: DGNOF) 는 Nassau의 Rosewood Baha Mar 호텔에서 열리는 Centurion One Capital 3rd Annual Bahamas Summit에 2025년 10월 28–29일에 발표할 예정입니다. CEO André Larente가 발표하고 투자자 미팅에 참석하며 패널에 참여합니다.
회사는 MDSAP 감사 성공를 언급했고 Saudi FDA, Health Canada 및 FDA의 규제 승인 대기 여부를 언급했습니다. 이 정상회담은 동부 표준시 기준 9:00 AM–5:00 PM 사이에 진행되며 프레젠테이션, 1:1 투자자 미팅, 패널 토론이 포함됩니다.
DIAGNOS (OTCQB: DGNOF) participera au 3e Sommet annuel des Bahamas de Centurion One Capital à Nassau, au Rosewood Baha Mar Hotel, les 28–29 octobre 2025. Le PDG André Larente présentera, participera à des rencontres avec les investisseurs et prendra part à un panel.
L'entreprise a signalé un audit MDSAP réussi et a fait référence à des approbations réglementaires en attente de Saudi FDA, Health Canada et de la FDA. Le sommet se déroule de 9h00 à 17h00 EDT et comprend des présentations, des rencontres investisseurs en tête-à-tête et des discussions de panel.
DIAGNOS (OTCQB: DGNOF) wird auf dem Centurion One Capital 3rd Annual Bahamas Summit am 28.–29. Oktober 2025 im Rosewood Baha Mar Hotel in Nassau präsentieren. CEO André Larente wird eine Präsentation halten, Investorenmeetings wahrnehmen und an einer Podiumsdiskussion teilnehmen.
Das Unternehmen meldete eine erfolgreiche MDSAP-Prüfung und verwies auf ausstehende behördliche Genehmigungen von Saudi FDA, Health Canada und der FDA. Der Gipfel läuft von 9:00 bis 17:00 Uhr EDT und bietet Präsentationen, 1x1-Investorentreffen und Podiumsdiskussionen.
DIAGNOS (OTCQB: DGNOF) ستقدم في قمة سنوية ثالثة ل Bahamas Summit من Centurion One Capital في فندق Rosewood Baha Mar في ناسو 28–29 أكتوبر 2025. سيقدم الرئيس التنفيذي André Larente، ويحضر اجتماعات المستثمرين ويشارك في جلسة نقاش.
أشارت الشركة إلى مراجعة MDSAP ناجحة وأشارت إلى الموافقات التنظيمية المعلقة من Saudi FDA, Health Canada وFDA. تستمر القمة من 9:00 صباحاً حتى 5:00 مساءً بتوقيت EDT وتتضمن عروض تقديمية واجتماعات 1x1 للمستثمرين وجلسات نقاش.
DIAGNOS (OTCQB: DGNOF) 将在 2025年10月28–29日 于拿骚的 Rosewood Baha Mar 酒店出席 Centurion One Capital 第3届 Bahamas Summit。CEO André Larente 将进行演讲，参加投资者会面并参与小组讨论。
公司提到一次 成功的 MDSAP 审核，并提到对 Saudi FDA、Health Canada 与 FDA 的监管批准待批。峰会时间为美东时间 9:00 AM–5:00 PM，内容包括演示、1对1 投资者会面和小组讨论。
- None.
- None.
Brossard, Quebec--(Newsfile Corp. - October 15, 2025) - Diagnos Inc. (TSXV: ADK) (OTCQB: DGNOF) (FSE: 4D4A) ("DIAGNOS" or the "Corporation"), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce it will be presenting at the Centurion One Capital 3rd Annual Bahamas Summit, a two-day invitation only event taking place at the exclusive Rosewood Baha Mar Hotel from Tuesday, October 28th to Wednesday, October 29th, 2025, in Nassau, Bahamas.
André Larente, CEO of DIAGNOS, will be presenting and attending investor meetings as well as participating on a panel discussion during the event. "With our recent successful MDSAP audit we are poised for growth due to pending in process regulatory approvals from Saudi FDA, Health Canada and the FDA. We are looking forward to present our Company to New investors at the Centurian One Capital summit, " said André Larente.
Centurion One Capital 3rd Annual Bahamas Summit is a two-day invitation only event that brings together the worlds leading small cap growth companies to an audience of global growth investors held at the Rosewood Baha Mar Hotel which epitomizes Bahamian refinement and sophistication. Set on the gorgeous white sand of Nassau's Cable Beach, the event will consist of a series of company presentations, 1x1 investor meetings, dynamic panels and networking over two days.
Summit Details
Format: Presentations, Panel Discussions and 1 X 1 Investor Meetings
Presentation Dates: Tuesday, October 28th and Wednesday, October 29th, 2025
Time: 9:00 AM EDT - 5:00 PM EDT
Venue: Rosewood Baha Mar Hotel
For more information and registration details, please visit: www.centuriononecapital.com/bahamas-summit.
About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.
Additional information is available at www.diagnos.com and www.sedarplus.com.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- 30 -
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270516
FAQ
When will DIAGNOS (DGNOF) present at the Centurion One Capital Bahamas Summit?
Who from DIAGNOS will attend the Centurion One Capital Summit on October 28–29, 2025?
What time are the DIAGNOS presentations at the Rosewood Baha Mar Hotel?
Will DIAGNOS discuss regulatory progress at the Centurion One Bahamas Summit?
How can investors register to attend the Centurion One Capital 3rd Annual Bahamas Summit?
What investor activities will DIAGNOS participate in at the October 2025 summit?
